Technology
Health
Biotechnology

Zai Lab

$35.42
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.91 (-2.50%) Today
$0.00 (0.00%) As of 4:28 PM EDT after-hours

Why Robinhood?

You can buy or sell Zai Lab and other stocks, options, ETFs, and crypto commission-free!

About ZLAB

Zai Lab Limited American Depositary Shares, also called Zai Lab, is a biopharmaceutical company, which engages in the licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need. Its product pipelines include ZL-2306, ZL-2401, FPA144, ETX2514, and ZL-2301. Read More The company was founded by Samantha Ying Du and Marietta Wu in 2014 and is headquartered in Shanghai, China.

Employees
309
Headquarters
Shanghai, Shanghai
Founded
2014
Market Cap
1.84B
Price-Earnings Ratio
Dividend Yield
Average Volume
139.88K
High Today
$36.68
Low Today
$35.22
Open Price
$36.54
Volume
102.27K
52 Week High
$36.78
52 Week Low
$14.29

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Therapy
Medical
Pharmaceutical
2017 IPO

ZLAB News

MarketWatchJul 2

Incyte enters license pact with Zai Lab to commercialize its cancer treatment in Greater China

193

ZLAB Earnings

-$0.28
-$0.25
-$0.21
-$0.18
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 29, Pre-Market

More ZLAB News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.